Phase 2 Herniorrhaphy Study for Opioid Elimination

Postoperative Pain Clinical Trial

Official title:

A Phase 2, Open-Label Study of HTX 011 in a Multimodal Analgesic Regimen for Decreased Opioid Use Following Unilateral Open Inguinal Herniorrhaphy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03695367
• Other study ID #: HTX-011-215
• Status: Completed
• Phase: Phase 2
• Start date: October 1, 2018
• Est. completion date: December 15, 2018

Study information

• Verified date: October 2021
• Source: Heron Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 2, open-label study in subjects undergoing unilateral open inguinal herniorrhaphy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 63
• Est. completion date: December 15, 2018
• Est. primary completion date: November 20, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Is scheduled to undergo a unilateral open inguinal herniorrhaphy with mesh under general anesthesia.

• Has an American Society of Anesthesiologists Physical Status of I, II, or III.

• Female subjects are eligible only if not pregnant, not lactating, not planning to become pregnant during the study, sterile; or using acceptable contraceptives.

Exclusion Criteria:

• Had any prior inguinal hernia repair except as a child (less than 6 years of age).

• Has a planned concurrent surgical procedure (eg, bilateral herniorrhaphy).

• Has a pre-existing concurrent acute or chronic painful physical/restrictive condition expected to require analgesic treatment in the postoperative period for pain.

• Has a contraindication or a known or suspected history of hypersensitivity or clinically significant idiosyncratic reaction to required study medications.

• Has known or suspected daily use of opioids for 7 or more consecutive days within the previous 6 months.

• Has taken any NSAIDs within least 10 days prior to the scheduled surgery.

• Has taken long-acting opioids within 3 days prior to the scheduled surgery.

• Has taken any opioids within 24 hours prior to the scheduled surgery.

• Has been administered bupivacaine within 5 days prior to the scheduled surgery.

• Has been administered any local anesthetic within 72 hours prior to the scheduled surgery.

• Has initiated treatment with study medications within 1 month prior to study drug administration that can impact pain control.

• Has been administered systemic steroids within 5 half-lives or 10 days prior to administration of study drug.

• Has a medical condition such that, in the opinion of the Investigator, participating in the study would pose a health risk to the subject or confound the postoperative assessments.

• As per subject history and/or medical records, has active infection or is currently undergoing treatment for Hepatitis B, Hepatitis C, or human immunodeficiency virus (HIV).

• Has uncontrolled anxiety, psychiatric, or neurological disorder.

• Had a malignancy in the last year, with the exception of nonmetastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.

• Has a known or suspected history of drug abuse, a positive drug screen on the day of surgery, or a recent history of alcohol abuse. Note: Subjects with a positive drug screen who are taking an allowed, prescribed medication that is known to result in a positive drug test (eg, amphetamine and dextroamphetamine for attention-deficit/hyperactivity disorder, benzodiazepine for anxiety disorder) may be eligible for participation in the study at the discretion of the Sponsor. Subjects taking any marijuana (medical or recreational) are not allowed to participate in the study.

• Previously participated in an HTX-011 study.

• Received an investigational product or device in a clinical trial within 30 days or within 5 elimination half-lives.

• Has undergone 3 or more surgeries within 12 months.

• Has a body mass index (BMI) >39 kg/m2.

Related Conditions & MeSH terms

• Pain, Postoperative
• Postoperative Pain

Intervention

Drug:
• HTX-011
HTX-011 (bupivacaine/meloxicam), 300 mg/ 9 mg via instillation.

Device:
• Luer lock applicator
Applicator for instillation.
• Vial access device
Device for withdrawal of drug product.

Drug:
• Ibuprofen
Ibuprofen, 600 mg.
• Acetaminophen
Acetaminophen, 1 g.
• Ketorolac
Intraoperative IV ketorolac.

Locations

Country	Name	City	State
United States	Anaheim Clinical Trials, LLC	Anaheim	California
United States	JBR Clinical Research	Draper	Utah
United States	JBR Clinical Research	Murray	Utah
United States	Lotus Clinical Research, LLC	Pasadena	California
United States	JBR Clinical Research	Salt Lake City	Utah

Sponsors (1)

Lead Sponsor	Collaborator
Heron Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Subjects Receiving no Opioid Rescue		72 hours
Secondary	Total Postoperative Opioid Consumption (in IV Morphine Milligram Equivalents [IV MME])		72 hours
Secondary	Percentge of Subjects Receiving no Opioid Rescue		0-24 hours, 24-48 hours, 24-72 hours, 48-72 hours
Secondary	Percentge of Subjects Receiving no Opioid Rescue		Day 28
Secondary	Percentge of Subjects in Severe Pain With Numeric Rating Scale (NRS-R; Windowed Worst Observation Carried Forward) of Pain Intensity Scores >7 on a Scale of 0-10 at Any Point. NRS-R for Pain Where 0 Equals no Pain and 10 Equals Worst Pain Imaginable.		72 hours